BEXLOSTERIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H16ClNO
Molecular Weight	249.736
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CCC3=CC(Cl)=CC=C3[C@@]1([H])CCC(=O)N2C

InChI

InChIKey=WQBIOEFDDDEARX-CHWSQXEVSA-N

InChI=1S/C14H16ClNO/c1-16-13-6-2-9-8-10(15)3-4-11(9)12(13)5-7-14(16)17/h3-4,8,12-13H,2,5-7H2,1H3/t12-,13-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C14H16ClNO
Molecular Weight	249.736
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8630232 | https://adisinsight.springer.com/drugs/800009929

LY 300502 is now called bexlosteride was developed as an inhibitor of the human-specific type I-selective steroid 5alpha-reductase. This drug was studied for patients with prostate cancer, however, has never been marketed.

Originator

Approval Year

PubMed

Title	Date	PubMed
Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor.	1996	8630232
Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.	2000 Aug	10901712

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:31:23 UTC 2023` Edited by `admin` on `Sat Dec 16 16:31:23 UTC 2023`
Record UNII	36X732P4P0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BEXLOSTERIDE

Official Name

English

LY-300502

Code

English

LY-191704

Code

English

(4aR,10bR)-8-Chloro-1,4,4a,5,6,10b-hexahydro-4-methylbenzo[f]quinolin-3(2H)-one

Common Name

English

bexlosteride [INN]

Common Name

English

BENZO(F)QUINOLIN-3(2H)-ONE, 8-CHLORO-1,4,4A,5,6,10B-HEXAHYDRO-4-METHYL-, (4AR-TRANS)

Common Name

English

LY300502

Code

English

BEXLOSTERIDE [USAN]

Common Name

English

Code System Code Type Description

FDA UNII

36X732P4P0